N/A
N=57
Screening for HPV and Cervical Cancer in Young Women With Perinatally Acquired HIV
HIV Infections · Human Papillomavirus Infection · Cervical Cancer
Bottom Line
View on ClinicalTrials.gov: NCT04587050 ↗Enrolled (actual)
57
Serious AEs
0.0%
Results posted
Dec 2024
Primary outcome: Primary: Prevalence of Abnormal Cervical Cytology — 12 Participants
Study Design & Population
- Study type
- Observational
- Phase
- N/A
- Interventions
- Human papillomavirus testing (Diagnostic_test); Cervical cytology (Diagnostic_test); HPV serology (Diagnostic_test)
- Age
- Adult, Older Adult · 18+ yrs
- Sex
- Female
- Sponsor
- Imperial College London
- Primary completion
- Jun 2023
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Prevalence of Abnormal Cervical Cytology |
12 | — |
| SECONDARY Prevalence of High Risk HPV by Subtype |
2; 0; 12; 32 | — |
| SECONDARY Prevalence of CIN2+ |
1 | — |
| SECONDARY HPV Serology (16/18) |
44; 1; 34; 0 | — |
Summary
This is a cross-sectional, observational study of high-risk HPV status, cervical cytology and HPV vaccine uptake and response in young women with perinatally acquired HIV.
Eligibility Criteria
Inclusion Criteria - Cohort 1:
- Perinatally acquired HIV aged 18+
- Sexually active
- Able to give informed consent
Inclusion Criteria - Cohort 2:
- Perinatally acquired HIV aged 18+
- Able to give informed consent
Exclusion Criteria - Cohort 1:
- Pregnancy
- Not sexually active
- Previous total abdominal hysterectomy
- Unable to give informed consent
Exclusion Criteria - Cohort 2:
- Unable to give informed consent
Data sourced from ClinicalTrials.gov (NCT04587050). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.